Formulation of Nonionic Surfactant Vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of nonionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesized by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. Flow cytometry and Western blotting were used to study the GFP expression knockdown, and significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This occurred in particular when using Tween 85, which was able to achieve more than 70% GFP knockdown. NISV were thus demonstrated to provide a promising and effective platform for therapeutic delivery of siRNA.

LanguageEnglish
Pages2450-2458
Number of pages9
JournalMolecular Pharmaceutics
Volume14
Issue number7
Early online date1 Jun 2017
DOIs
Publication statusPublished - 3 Jul 2017

Fingerprint

Microfluidics
Surface-Active Agents
Small Interfering RNA
Green Fluorescent Proteins
Neoplasms
Therapeutics
Polysorbates
Flow Cytometry
Western Blotting
Genes

Keywords

  • drug delivery
  • microfluidics
  • nonionic surfactant vesicles
  • RNA interference

Cite this

@article{8bf9d71831804fc1b607bd25f2ce3212,
title = "Formulation of Nonionic Surfactant Vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells",
abstract = "Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of nonionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesized by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. Flow cytometry and Western blotting were used to study the GFP expression knockdown, and significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This occurred in particular when using Tween 85, which was able to achieve more than 70{\%} GFP knockdown. NISV were thus demonstrated to provide a promising and effective platform for therapeutic delivery of siRNA.",
keywords = "drug delivery, microfluidics, nonionic surfactant vesicles, RNA interference",
author = "Obeid, {Mohammad A.} and Ashref Elburi and Young, {Louise C.} and Mullen, {Alexander B.} and Tate, {Rothwelle J.} and Ferro, {Valerie A.}",
year = "2017",
month = "7",
day = "3",
doi = "10.1021/acs.molpharmaceut.7b00352",
language = "English",
volume = "14",
pages = "2450--2458",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - Formulation of Nonionic Surfactant Vesicles (NISV) prepared by microfluidics for therapeutic delivery of siRNA into cancer cells

AU - Obeid, Mohammad A.

AU - Elburi, Ashref

AU - Young, Louise C.

AU - Mullen, Alexander B.

AU - Tate, Rothwelle J.

AU - Ferro, Valerie A.

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of nonionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesized by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. Flow cytometry and Western blotting were used to study the GFP expression knockdown, and significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This occurred in particular when using Tween 85, which was able to achieve more than 70% GFP knockdown. NISV were thus demonstrated to provide a promising and effective platform for therapeutic delivery of siRNA.

AB - Small interfering RNAs (siRNA) have a broad potential as therapeutic agents to reversibly silence any target gene of interest. The clinical application of siRNA requires the use of safe and effective delivery systems. In this study, we investigated the use of nonionic surfactant vesicles (NISV) for the delivery of siRNA. Different types of NISV formulations were synthesized by microfluidic mixing and then evaluated for their physiochemical properties and cytotoxicity. The ability of the NISV to carry and transfect siRNA targeting green fluorescent protein (GFP) into A549 that stably express GFP (copGFP-A549) was evaluated. Flow cytometry and Western blotting were used to study the GFP expression knockdown, and significant knockdown was observed as a result of siRNA delivery to the cells by NISV. This occurred in particular when using Tween 85, which was able to achieve more than 70% GFP knockdown. NISV were thus demonstrated to provide a promising and effective platform for therapeutic delivery of siRNA.

KW - drug delivery

KW - microfluidics

KW - nonionic surfactant vesicles

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=85021701734&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.7b00352

DO - 10.1021/acs.molpharmaceut.7b00352

M3 - Article

VL - 14

SP - 2450

EP - 2458

JO - Molecular Pharmaceutics

T2 - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 7

ER -